t
On 18 June 2024, Tissue Regenix Group plc issued and allotted 821,167 new ordinary shares following the exercise of an aggregate 821,167 share options by Daniel Lee (CEO), David Cocke (CFO), Kirsten Lund (PDMR), and other employees. As part of these transactions, Daniel Lee sold 87,611 shares, David Cocke sold 63,207 shares, and Kirsten Lund sold 60,751 shares, all at 61 pence per share. Application has been made for these new shares to be admitted to AIM on 27 June 2024, at which point the Company will have 71,395,635 total voting rights.
| Date | 18 Jun 2024 |
| Time | 17:15:33 |
| Category | Director/PDMR dealings |
| ID | 9417S |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group', or the 'Company')
Exercise of Options, Director Dealing and Total Voting Rights
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that the Company has issued and allotted 821,167 new ordinary shares of 0.1 pence each ("Ordinary Shares") following the exercise of an aggregate number of 821,167 share options (the "Options") by Daniel Lee (Chief Executive Officer), David Cocke (Chief Financial Officer), Kirsten Lund (PDMR) and other employees, issued under the Company's Long-Term Incentive Plan. Each employee disposed of such number of Ordinary Shares required to cover the associated cost attached to the exercise of Options.
|
|
Numer of Options exercised |
Numbers of Ordinary Shares sold |
Price of Ordinary Shares sold |
Resultant beneficial holding |
% of issued share capital |
|
Daniel Lee |
283,216 |
87,611 |
61 pence |
282,512 |
0.4 |
|
David Cocke |
146,491 |
63,207 |
61 pence |
154,489 |
0.2 |
|
Kirsten Lund |
109,091 |
60,751 |
61 pence |
113,557 |
0.2 |
Application has been made for the 821,167 new Ordinary Shares to be admitted to trading on AIM. It is expected that dealings in these new Ordinary Shares will commence at 8.00 a.m. on 27 June 2024. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Following Admission, the Company will have in issue a total of 71,395,635 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the number of total voting rights for the Company will be 71,395,635.
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
|
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance |
|
|
|
Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings/Charlotte Edgar |
||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.
Further details of the PDMR dealing are included below. This information has been provided in accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Daniel Lee |
|
|
2. |
Reason for the Notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification/Amendment |
|
|
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Tissue Regenix Group plc |
|
|
b) |
LEI |
213800PNOD5UHQUFJI36 |
|
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.1p each
|
|
|
Identification code |
GB00B5SGVL29 |
||
|
b) |
Nature of the transaction |
Exercise of options and sale of Ordinary Shares
|
|
|
c) |
Price(s) and volume(s) |
Options exercised: 283,216 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 87,611 shares at 61 pence each |
|
|
d) |
Aggregated information: · Aggregated volume · Price |
N/A |
|
|
e) |
Date of the transaction |
18 June 2024 |
|
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
|
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
David Cocke |
|
|
2. |
Reason for the Notification |
||
|
a) |
Position/status |
Chief Financial Officer |
|
|
b) |
Initial notification/Amendment |
|
|
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Tissue Regenix Group plc |
|
|
b) |
LEI |
213800PNOD5UHQUFJI36 |
|
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.1p each
|
|
|
Identification code |
GB00B5SGVL29 |
||
|
b) |
Nature of the transaction |
Exercise of options and sale of Ordinary Shares
|
|
|
c) |
Price(s) and volume(s) |
Options exercised: 146,491 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 63,207 shares at 61 pence each |
|
|
d) |
Aggregated information: · Aggregated volume · Price |
N/A |
|
|
e) |
Date of the transaction |
18 June 2024 |
|
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
|
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
||
|
a) |
Name |
Kirsten Lund |
|
|
2. |
Reason for the Notification |
||
|
a) |
Position/status |
PDMR |
|
|
b) |
Initial notification/Amendment |
|
|
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
Tissue Regenix Group plc |
|
|
b) |
LEI |
213800PNOD5UHQUFJI36 |
|
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.1p each
|
|
|
Identification code |
GB00B5SGVL29 |
||
|
b) |
Nature of the transaction |
Exercise of options and sale of Ordinary Shares
|
|
|
c) |
Price(s) and volume(s) |
Options exercised: 109,091 Ordinary Shares at an exercise price of 10 pence each Ordinary Shares sold: 60,751 shares at 61 pence each |
|
|
d) |
Aggregated information: · Aggregated volume · Price |
N/A |
|
|
e) |
Date of the transaction |
18 June 2024 |
|
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
|